Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

TY - JOUR

T1 - Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH

AU - Cornell, Robert

AU - Hari, Parameswaran

AU - Tang, Shijie

AU - Biran, Noa

AU - Callander, Natalie

AU - Chari, Ajai

AU - Chhabra, Saurabh

AU - Fiala, Mark A.

AU - Gahvari, Zhubin

AU - Gandhi, Ujjawal

AU - Godby, Kelly

AU - Gupta, Ridhi

AU - Jagannath, Sundar

AU - Jagosky, Megan

AU - Kang, Yubin

AU - Kansagra, Ankit

AU - Kauffman, Michael

AU - Kodali, Saranya

AU - Kumar, Shaji K.

AU - Lakshman, Arjun

AU - Liedtke, Michaela

AU - Lonial, Sagar

AU - Ma, Xiwen

AU - Malek, Ehsan

AU - Mansour, Joshua

AU - McGehee, Elizabeth F.

AU - Neppalli, Amarendra

AU - Paul, Barry

AU - Richardson, Paul

AU - Scott, Emma C.

AU - Shacham, Sharon

AU - Shah, Jatin

AU - Siegel, David S.

AU - Umyarova, Elvira

AU - Usmani, Saad Z.

AU - Varnado, William

AU - Vij, Ravi

AU - Costa, Luciano

N1 - Funding Information: R.C. reports honoraria from Karyopharm Therapeutics, Takeda, Janssen, Sanofi, and GlaxoSmithKline; P.H. reports honoraria from Bristol Myers Squibb, Takeda, Amgen, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Sanofi, and Pharmacyclics; S.T., J.S., M.K., and X.M. report being employed by and owning stock in Karyopharm Therapeutics; N.B. reports honoraria and speakers' bureau participation for Celgene, Amgen, Janssen, and Takeda; consulting or advisory role fees and reimbursement of travel, accommodations, or other expenses from Celgene, Amgen, and Takeda; and research funding from Merck and Amgen; N.C. reports research support from Cellectar; A.C. reports receiving grant support and consulting fees from Millennium/Takeda; grant support, advisory board fees, and consulting fees from Celgene, Novartis Pharmaceuticals, Amgen, and Janssen; consulting fees from Bristol Myers Squibb; advisory board fees from Sanofi and Oncopeptides; grant support from Pharmacyclics; and grant support and advisory board fees from Seattle Genetics; S.C. reports receiving honorarium from Takeda Pharmaceuticals; Funding Information: S.J. reports receiving advisory board fees and consulting fees from Bristol Myers Squibb, Janssen Pharmaceuticals, and Merck; Y.K. reports receiving advisory board fees from Takeda and grant support from InCyte; A.K. reports receiving advisory board fees from Celgene, Janssen, Karyopharm Therapeutics, Takeda, Pfizer and Pharmacyclics; S.K.K. reports receiving advisory board fees from AbbVie, Celgene, Janssen, Takeda Pharmaceuticals, Adaptive Biotechnologies, Kite Pharma, MedImmune/AstraZeneca; receiving research funding from AbbVie, Celgene, Janssen, Merck, Novartis, Roche, Sanofi, Takeda Pharmaceuticals, Kite Pharma and MedImmune/AstraZeneca; and is a member of the Independent Review Committee for Oncopeptides; M.L. reports receiving personal fees from Amgen, Celgene, Pfizer, Takeda, and Janssen; S.L. reports receiving advisory board fees from AbbVie, Amgen, Celgene, Takeda, Janssen Oncology, Juno Therapeutics, Novartis, Merck, Bristol Myers Squibb, and GlaxoSmithKline; and receiving research funding from Bristol Myers Squibb, Celgene, and Takeda; E.M. reports receiving advisory board and speaker fees from Takeda, Sanofi, Amgen and Celgene; speaker fees from Janssen; research funding from Medpacto Inc. and Cumberland; A.N. reports receiving advisory board fees from Amgen; B.P. reports receiving honoraria from Celgene; consulting fees from Amgen and Janssen; P.R. reports receiving grant support and honoraria from Oncopeptides, Celgene, and Takeda; grant support from Bristol Myers Squibb; and honoraria from Amgen, Janssen, and Karyopharm Therapeutics; E.S. reports being employed by GlaxoSmithKline; S.S. reports being employed by and owning stock in Karyopharm Therapeutics, holding patents (8 999 996, 9 079 865, 9 714 226, PCT/US12/048319, and I574957) on hydrazide‐containing nuclear transport modulators and uses, and holding pending patents (PCT/US12/048319, 499/2012, PI20102724, and 012000928) on hydrazide‐containing nuclear transport modulators and uses; D.S. reports receiving honoraria and consulting or advisory role fees for Celgene, Amgen, Merck, Janssen, Bristol Myers Squibb, Takeda, and Karyopharm Therapeutics; speakers' bureau participation for Celgene, Amgen, Merck, Janssen, Bristol Myers Squibb, and Takeda; and research funding from Celgene; S.U. reports receiving consulting fees from Abbvie, Amgen Inc, Bristol Myers Squibb, Celgene, EdoPharma, GlaxoSmithKline, Janssen, Merck, Sanofi, Seattle Genetics, Skyline Dx, Takeda, and TeneoBio; and research funding from Amgen, Array Biopharma, Bristol Myers Squibb, Celgene, Janssen, Merck, Pharmacyclics, Prothena, Sanofi, Seattle Genetics, Skyline Dx, and Takeda; R.V. reports receiving advisory board fees from Bristol Myers Squibb, Takeda, Janssen, Karyopharm Therapeutics, Securabio, and Genentech; and research funding from Bristol Myers Squibb and Takeda; L.C. reports research funding from Amgen and Janssen; and honoraria from Karyopharm Therapeutics, Celgene, Amgen, Janssen, and Sanofi. M.F., Z.G., U.G., K.G., R.G., M.J., S.K., A.L., J.M., E.F.M., E.U., and W.V. declare no conflict of interest.

PY - 2021/1

Y1 - 2021/1

UR - http://www.scopus.com/inward/record.url?scp=85092920395&partnerID=8YFLogxK

U2 - 10.1002/ajh.26010

DO - 10.1002/ajh.26010

M3 - Letter

C2 - 32974944

AN - SCOPUS:85092920395

VL - 96

SP - E5-E8

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 1

ER -